NOVEN
TO PRESENT AT THOMAS WEISEL PARTNERS |
BackMiami, FL, August
30, 2006 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced
that Robert C. Strauss, its President, CEO & Chairman, is scheduled
to provide an update on Noven’s business and prospects at the
Thomas Weisel Partners Healthcare Conference in Boston on Wednesday,
September 6, 2006, at 10:55 a.m. Eastern Time. The public is invited
to listen to the presentation live via webcast at www.noven.com, and
a replay will be available for at least two weeks at the same site.
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is
a leading developer of advanced transdermal drug delivery technologies
and prescription
transdermal products. Noven’s prescription patches are approved in
over 30 countries and include Vivelle-Dot™ (the most prescribed estrogen
patch in the U.S.) and Daytrana™ (the first and only patch approved
for the treatment of ADHD). A range of new patches is being investigated
and developed in collaboration with Shire plc, P&G Pharmaceuticals,
Endo Pharmaceuticals Inc. and others. Noven is committed to expanding
the universe of available transdermal therapies for the benefit of patients,
partners and shareholders. See www.noven.com for additional information.
| Contact: Alina Bowman Investor Relations Coordinator (305) 253-1916 |
Copyright © 2006 Noven Pharmaceuticals, Inc. All rights reserved.